Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-11-20
2000-01-04
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514866, 530303, 530304, C07K 1462, A61K 3828
Patent
active
060110074
ABSTRACT:
The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the .epsilon.-amino group of Lys.sup.B29 ; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the .epsilon.-amino group of Lys.sup.B29 has a lipophilic substituent; and any Zn.sup.2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe.sup.B1 is present, then the insulin derivative is always present as a Zn.sup.2+ complex.
REFERENCES:
patent: 3528960 (1970-09-01), Haas et al.
patent: 3823125 (1974-07-01), Grant et al.
patent: 3868356 (1975-02-01), Smyth
patent: 3950517 (1976-04-01), Lindsay et al.
patent: 4645740 (1987-02-01), Breddam et al.
patent: 5008241 (1991-04-01), Markussen et al.
patent: 5208217 (1993-05-01), Panayotis
Markussen et al. Prot. Eng. 1:205-213, 1987.
Markussen et al. Prot. Eng. 2:157-166, 1988.
Gammelhoft. Phys. Rev. 64:1321-1378, 1984.
Samuel et al., (1978) Clin. Exp. Immunol. 33:252-260.
Kurtz et al., (1983) Diabetologia 25:322-324.
Lindsay and Shall: The Acetylation of Insulin Biochem: (1991) 121, pp. 737-745.
Brange and Langkjaer: Chemical Stability of Insulin Acta Pharm. Nord.4(3) 149-158 (1992).
MIMS Annual 1991, Section 6d "Insulin Preparations" (IMS Publishing).
MIMS Annual 1993, Section 6d "Insulin Preparations" (IMS Publishing).
Prescription Products Guide 1992, pp. 942-944, 957-958 and 1307-1308.
J. Schlichtkrull, "Insulin Crystals" (Ejnar Munksgaard) 1958, pp. 21-33.
A Marble et al., Joslin's Diabetes Mellitus, 12th Edition, 1985, pp. 380-382.
Schade: Intensive Insulin Therapy, Exerpta Medica 1983, pp. 7 and 304.
W.O. Foye: Principles of Medicinal Chemistry 1974, pp. 563-565.
Doerge: Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry 1982, pp. 774-776.
Andersen Asser Sloth
Halstrom John
Havelund Svend
Jonassen Ib
Markussen Jan
Lambiris, Esq. Elias
Novo Nordisk A S
Saoud Christine
Ulm John
Zelson Esq. Steve T.
LandOfFree
Acylated insulin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated insulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated insulin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072667